Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Immunic is developing three small molecule products: its lead development program, IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. Immunic announced positive results from its phase 2 EMPhASIS trial of IMU-838 in patients with relapsing-remitting multiple sclerosis, reporting achievement of both primary and key secondary endpoints with high statistical significance. IMU-838 is also in phase 2 clinical development for ulcerative colitis and COVID-19, with an additional phase 2 trial considered in Crohn's disease. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is ongoing at the Mayo Clinic.
Company profile
Ticker
IMUX
Exchange
Website
CEO
Daniel Vitt
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
VITAL THERAPIES INC
SEC CIK
Corporate docs
Subsidiaries
Immunic AG ...
IMUX stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
13 Mar 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update
23 Feb 23
8-K
Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need
9 Feb 23
8-K
Departure of Directors or Certain Officers
19 Jan 23
8-K
Entry into a Material Definitive Agreement
30 Dec 22
EFFECT
Notice of effectiveness
21 Dec 22
424B3
Prospectus supplement
20 Dec 22
CORRESP
Correspondence with SEC
16 Dec 22
UPLOAD
Letter from SEC
15 Dec 22
Transcripts
IMUX
Earnings call transcript
2022 Q4
23 Feb 23
IMUX
Earnings call transcript
2022 Q2
6 Aug 22
IMUX
Earnings call transcript
2022 Q1
10 May 22
IMUX
Earnings call transcript
2021 Q4
24 Feb 22
IMUX
Earnings call transcript
2021 Q3
6 Nov 21
IMUX
Earnings call transcript
2020 Q2
3 Aug 20
IMUX
Earnings call transcript
2018 Q2
7 Aug 18
IMUX
Earnings call transcript
2018 Q1
8 May 18
IMUX
Earnings call transcript
2017 Q4
13 Mar 18
IMUX
Earnings call transcript
2017 Q3
25 Oct 17
Latest ownership filings
SC 13D/A
LSP V Cooperatieve U.A.
24 Feb 23
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 23
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 23
SC 13G/A
Deep Track Capital, LP
14 Feb 23
SC 13D/A
Global Life Bioventure V Sarl
13 Feb 23
4
Andreas Muehler
6 Jan 23
4
Duane Nash
6 Jan 23
4
Glenn Whaley
6 Jan 23
4
Daniel Vitt
6 Jan 23
4
Joerg Neermann
15 Dec 22
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 106.75 mm | 106.75 mm | 106.75 mm | 106.75 mm | 106.75 mm | 106.75 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 19.11 mm | 9.96 mm | 5.03 mm | 5.43 mm |
| Cash used (since last report) | n/a | n/a | 53.46 mm | 27.86 mm | 14.09 mm | 15.19 mm |
| Cash remaining | n/a | n/a | 53.28 mm | 78.89 mm | 92.66 mm | 91.56 mm |
| Runway (months of cash) | n/a | n/a | 2.8 | 7.9 | 18.4 | 16.9 |
Institutional ownership, Q4 2022
71.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 67 |
| Opened positions | 20 |
| Closed positions | 22 |
| Increased positions | 23 |
| Reduced positions | 14 |
| 13F shares | Current |
|---|---|
| Total value | 27.60 bn |
| Total shares | 31.53 mm |
| Total puts | 261.80 k |
| Total calls | 320.70 k |
| Total put/call ratio | 0.8 |
| Largest owners | Shares | Value |
|---|---|---|
| Deep Track Capital | 4.02 mm | $0.00 |
| RTW Investments | 3.86 mm | $5.41 bn |
| Roi Verwaltungs GMBH | 1.97 mm | $2.86 mm |
| Commodore Capital | 1.80 mm | $2.52 mm |
| Omega Fund Management | 1.79 mm | $2.50 bn |
| Gratus Capital | 1.67 mm | $2.34 bn |
| Artal | 1.27 mm | $1.79 mm |
| BVF | 1.15 mm | $1.61 bn |
| Vanguard | 1.07 mm | $1.50 bn |
| Cowen And | 791.02 k | $1.11 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 2 Jan 23 | Vitt Daniel | Stock Option Common Stock | Grant | Acquire A | No | No | 1.4 | 300,000 | 420.00 k | 300,000 |
| 2 Jan 23 | Nash Duane | Stock Option Common Stock | Grant | Acquire A | No | No | 1.4 | 132,000 | 184.80 k | 132,000 |
| 2 Jan 23 | Whaley Glenn | Stock Option Common Stock | Grant | Acquire A | No | No | 1.4 | 110,000 | 154.00 k | 110,000 |
| 2 Jan 23 | Andreas Muehler | Stock Option Common Stock | Grant | Acquire A | No | No | 1.4 | 132,000 | 184.80 k | 132,000 |
| 14 Dec 22 | Neermann Joerg | Common Stock | Buy | Acquire P | No | No | 1.256 | 47,000 | 59.03 k | 100,000 |
| 13 Dec 22 | Neermann Joerg | Common Stock | Buy | Acquire P | No | No | 1.246 | 35,000 | 43.61 k | 53,000 |
News
Immunic FY EPS $(3.78) Misses $(2.90) Estimate; $116.4M In Cash, Cash Equivalents and Investments Expected to Fund Immunic Into Q4 Of 2024
23 Feb 23
Earnings Scheduled For February 23, 2023
23 Feb 23
Preview: Immunic's Earnings
22 Feb 23
Wedbush Assumes Immunic at Outperform, Announces Price Target of $5
31 Jan 23
Press releases
Thinking about buying stock in Thermogenesis, UiPath, Snap, Immunic, or Enovix?
16 Mar 23
Immunic to Participate in Investor and Scientific Conferences in March
2 Mar 23
Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update
23 Feb 23
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023
22 Feb 23
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update
16 Feb 23